Teva Pharma (TEVA) volatility increases into conference call to discuss restructuring
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Price: $12.86 +0.63%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: +0.8%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: +0.8%
Join SI Premium – FREE
TevDecember call option implied volatility is at 119, January is at 57; compared to its 52-week range of 24 to 66 into conference call to discuss restructuring and additional measures to improve its business and financial performance on December 14.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- HUYA Inc. (HUYA) May 5 calls active
- Verizon Communications (VZ) April weekly option implied volatility into quarter results
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
